The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …

Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …

Ploidy abnormalities are a hallmark of cancer, but their impact on the evolution and
outcomes of cancers is unknown. Here, we identified whole-genome doubling (WGD) in the …

The horizontal transfer of mtDNA and its role in mediating resistance to therapy and an exit
from dormancy have never been investigated. Here we identified the full mitochondrial …

Deregulation of the cyclin D‐CDK4/6‐INK4‐RB pathway leading to uncontrolled cell
proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 …

Importance The choice between chemotherapy and endocrine therapy as first-line treatment
for hormone receptor–positive, ERBB2 (also known as HER2)-negative metastatic breast …

Curcumin is a natural compound that appears to be promising for clinical application, as it
has been shown in in vitro and in vivo studies to exert antitumor effects by modulating …

Simple Summary Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are widely used to
treat metastatic hormone receptor-positive/human epidermal growth factor receptor 2 …

Breast cancer is a heterogeneous disease manifesting diversity at the molecular,
histological and clinical level. The development of breast cancer classification was centered …

Cannabinoids (CBs) from Cannabis sativa provide relief for tumor-associated symptoms
(including nausea, anorexia, and neuropathic pain) in the palliative treatment of cancer …